Dysregulated thrombospondin 1 and miRNA-29a-3p in severe COVID-19.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 12 2022
08 12 2022
Historique:
received:
05
05
2022
accepted:
31
10
2022
entrez:
8
12
2022
pubmed:
9
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Although nearly a fifth of symptomatic COVID-19 patients suffers from severe pulmonary inflammation, the mechanism of developing severe illness is not yet fully understood. To identify significantly altered genes in severe COVID-19, we generated messenger RNA and micro-RNA profiling data of peripheral blood mononuclear cells (PBMCs) from five COVID-19 patients (2 severe and 3 mild patients) and three healthy controls (HC). For further evaluation, two publicly available RNA-Seq datasets (GSE157103 and GSE152418) and one single-cell RNA-Seq dataset (GSE174072) were employed. Based on RNA-Seq datasets, thrombospondin 1 (THBS1) and interleukin-17 receptor A (IL17RA) were significantly upregulated in severe COVID-19 patients' blood. From single-cell RNA-sequencing data, IL17RA level is increased in monocytes and neutrophils, whereas THBS1 level is mainly increased in the platelets. Moreover, we identified three differentially expressed microRNAs in severe COVID-19 using micro-RNA sequencings. Intriguingly, hsa-miR-29a-3p significantly downregulated in severe COVID-19 was predicted to bind the 3'-untranslated regions of both IL17RA and THBS1 mRNAs. Further validation analysis of our cohort (8 HC, 7 severe and 8 mild patients) showed that THBS1, but not IL17RA, was significantly upregulated, whereas hsa-miR-29a-3p was downregulated, in PBMCs from severe patients. These findings strongly suggest that dysregulated expression of THBS1, IL17RA, and hsa-miR-29a-3p involves severe COVID-19.
Identifiants
pubmed: 36481664
doi: 10.1038/s41598-022-23533-x
pii: 10.1038/s41598-022-23533-x
pmc: PMC9732043
doi:
Substances chimiques
Thrombospondin 1
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21227Informations de copyright
© 2022. The Author(s).
Références
Biol Chem. 2021 Dec 22;403(2):231-241
pubmed: 34957734
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Exp Med. 2005 Jan 17;201(2):233-40
pubmed: 15657292
Cells. 2021 Jul 12;10(7):
pubmed: 34359932
PLoS One. 2018 Oct 18;13(10):e0206239
pubmed: 30335862
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Curr Opin Virol. 2022 Feb;52:30-38
pubmed: 34814102
J Cell Mol Med. 2018 Apr;22(4):2086-2097
pubmed: 29441713
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Int Immunopharmacol. 2022 Jan;102:108402
pubmed: 34863654
Noncoding RNA Res. 2020 Dec;5(4):222-231
pubmed: 33251388
J Virus Erad. 2017 Oct 1;3(4):185-191
pubmed: 29057080
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Arch Virol. 2021 Feb;166(2):363-373
pubmed: 33206218
Viruses. 2021 Aug 11;13(8):
pubmed: 34452458
JAMA Netw Open. 2020 Jun 1;3(6):e2012270
pubmed: 32543702
Nat Rev Immunol. 2014 Sep;14(9):585-600
pubmed: 25145755
Viruses. 2021 Dec 27;14(1):
pubmed: 35062245
Matrix Biol. 2013 Aug 8;32(6):316-24
pubmed: 23499828
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Antibodies (Basel). 2020 Sep 01;9(3):
pubmed: 32882841
Front Cardiovasc Med. 2021 Dec 17;8:785738
pubmed: 34977191
Retrovirology. 2014 Dec 09;11:108
pubmed: 25486977
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Int Immunopharmacol. 2021 Jan;90:107225
pubmed: 33302033
Eur J Heart Fail. 2021 Mar;23(3):468-475
pubmed: 33421274
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Nat Immunol. 2007 Dec;8(12):1390-7
pubmed: 17994024
JAMA Netw Open. 2020 Sep 1;3(9):e2022310
pubmed: 32965502
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Nat Rev Immunol. 2009 Aug;9(8):556-67
pubmed: 19575028
J Exp Med. 2021 Aug 2;218(8):
pubmed: 34128959
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2293-305
pubmed: 9351403
Nat Rev Immunol. 2010 Feb;10(2):111-22
pubmed: 20098459
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Biol Chem. 1980 Dec 25;255(24):11629-32
pubmed: 6777381
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Biomolecules. 2021 Oct 20;11(11):
pubmed: 34827548
Cells. 2021 Jun 19;10(6):
pubmed: 34205262
Life Sci. 2020 Nov 15;261:118355
pubmed: 32871183
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
Eur J Med Res. 2021 Jul 13;26(1):75
pubmed: 34256840
BMC Infect Dis. 2021 Jan 12;21(1):57
pubmed: 33435865
Res Pract Thromb Haemost. 2021 Dec 17;5(8):e12638
pubmed: 34977448
Antib Ther. 2020 Jul;3(3):179-192
pubmed: 33244513
Medicine (Baltimore). 2021 Dec 17;100(50):e28302
pubmed: 34918709
Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):
pubmed: 34903581
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Nature. 2007 Feb 8;445(7128):648-51
pubmed: 17187052
Cell Death Dis. 2016 Sep 08;7(9):e2368
pubmed: 27607583
Scand J Clin Lab Invest. 2021 Dec;81(8):679-686
pubmed: 34762008
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191
pubmed: 33043231
Front Immunol. 2019 Jun 04;10:1268
pubmed: 31214201
Nature. 2011 Jul 17;475(7357):514-8
pubmed: 21765430
Int J Environ Res Public Health. 2021 Dec 08;18(24):
pubmed: 34948552
Transl Res. 2021 Oct;236:147-159
pubmed: 34048985
Curr Opin Immunol. 2008 Dec;20(6):697-702
pubmed: 18832032
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Immunity. 2020 Nov 17;53(5):1108-1122.e5
pubmed: 33128875
J Korean Med Sci. 2020 Sep 28;35(38):e343
pubmed: 32989935
J Clin Lab Anal. 2020 Oct;34(10):e23590
pubmed: 32960473
Cell Syst. 2021 Jan 20;12(1):23-40.e7
pubmed: 33096026
Virus Res. 2022 Jan 15;308:198631
pubmed: 34788642